Menu Search
Equities

Celon Pharma SA

  • Add to watchlist
  • Add to portfolio
  • Add an alert
8RP:STU

Celon Pharma SA

Actions
  • Price (EUR)5.29
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change-3.47%
  • Beta0.6476
Data delayed at least 15 minutes, as of Feb 13 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Celon Pharma SA is a Poland-based company primarily engaged in the pharmaceuticals manufacture. The Company focuses on research, development and production of generic drugs for cancer, neurological diseases, diabetes and other metabolic disorders treatment, among others. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir and Valzek, as well as inhalation powder, such as Salmex. The Company's research center develops pharmaceuticals within a number of therapeutic areas, including oncology, neurology, as well as inflammatory and metabolic diseases. The Company is a subsidiary of Glatton sp z o o.

  • Revenue in PLN (TTM)228.56m
  • Net income in PLN-122.11m
  • Incorporated2012
  • Employees566.00
  • Location
    Celon Pharma SAOgrodowa 2A, Kielpin 05-092PolandPOL
  • Phone+48 227515933
  • Fax+48 227515933
  • Websitehttps://celonpharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.